Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial

Solidarity Finland Investigators; Olli P.O. Nevalainen; Saana Horstia; Sanna Laakkonen; Jarno Rutanen; Jussi M.J. Mustonen; Ilkka E.J. Kalliala; Hanna Ansakorpi; Hanna Riikka Kreivi; Pauliina Kuutti; Juuso Paajanen; Seppo Parkkila; Erja Leena Paukkeri; Markus Perola; Negar Pourjamal; Andreas Renner; Tuomas Rosberg; Taija Rutanen; Joni Savolainen; Jari K. Haukka; Gordon H. Guyatt; Kari A.O. Tikkinen

doi:10.1038/s41467-022-33825-5

Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial

Solidarity Finland Investigators, Olli P.O. Nevalainen, Saana Horstia, Sanna Laakkonen, Jarno Rutanen, Jussi M.J. Mustonen, Ilkka E.J. Kalliala, Hanna Ansakorpi, Hanna Riikka Kreivi, Pauliina Kuutti, Juuso Paajanen, Seppo Parkkila, Erja Leena Paukkeri, Markus Perola, Negar Pourjamal, Andreas Renner, Tuomas Rosberg, Taija Rutanen, Joni Savolainen, Jari K. HaukkaGordon H. Guyatt, Kari A.O. Tikkinen

Research output: Contribution to journal › Article › Scientific › peer-review

27 Citations (Scopus)

13 Downloads (Pure)

Abstract

We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.

Original language	English
Article number	6152
Number of pages	6
Journal	Nature Communications
Volume	13
DOIs	https://doi.org/10.1038/s41467-022-33825-5
Publication status	Published - Oct 2022
Publication type	A1 Journal article-refereed

Funding

The authors would like to thank the participating patients, their families, and the hospital staff. The Academy of Finland (335527; K.A.O.T.), Foundation of the Finnish Anti-Tuberculosis Association (K.A.O.T.), Helsinki University Hospital (TYH2022330; K.A.O.T.), Päivikki and Sakari Sohlberg Foundation (K.A.O.T.), Sigrid Jusélius Foundation (K.A.O.T.), Tampere Tuberculosis Foundation (J.R. and K.A.O.T.), and Tampere University Hospital State Research Funding (9AC085; J.R.) funded this study. World Health Organization (WHO) provided the study drug (remdesivir), donated by Gilead Sciences. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. The authors would like to thank the participating patients, their families, and the hospital staff. The Academy of Finland (335527; K.A.O.T.), Foundation of the Finnish Anti-Tuberculosis Association (K.A.O.T.), Helsinki University Hospital (TYH2022330; K.A.O.T.), Päivikki and Sakari Sohlberg Foundation (K.A.O.T.), Sigrid Jusélius Foundation (K.A.O.T.), Tampere Tuberculosis Foundation (J.R. and K.A.O.T.), and Tampere University Hospital State Research Funding (9AC085; J.R.) funded this study. World Health Organization (WHO) provided the study drug (remdesivir), donated by Gilead Sciences. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.

Publication forum classification

Publication forum level 3

ASJC Scopus subject areas

General Chemistry
General Biochemistry,Genetics and Molecular Biology
General
General Physics and Astronomy

Access to Document

10.1038/s41467-022-33825-5Licence: CC BY

s41467-022-33825-5Final published version, 886 KBLicence: CC BY

https://urn.fi/URN:NBN:fi:tuni-202211018042Licence: CC BY

Cite this

Solidarity Finland Investigators, Nevalainen, O. P. O., Horstia, S., Laakkonen, S., Rutanen, J., Mustonen, J. M. J., Kalliala, I. E. J., Ansakorpi, H., Kreivi, H. R., Kuutti, P., Paajanen, J., Parkkila, S., Paukkeri, E. L., Perola, M., Pourjamal, N., Renner, A., Rosberg, T., Rutanen, T., Savolainen, J., ... Tikkinen, K. A. O. (2022). Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial. Nature Communications, 13, Article 6152. https://doi.org/10.1038/s41467-022-33825-5

@article{e61c4a4aef0448e8b2c34b40ac94779d,

title = "Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial",

abstract = "We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.",

author = "{Solidarity Finland Investigators} and Nevalainen, {Olli P.O.} and Saana Horstia and Sanna Laakkonen and Jarno Rutanen and Mustonen, {Jussi M.J.} and Kalliala, {Ilkka E.J.} and Hanna Ansakorpi and Kreivi, {Hanna Riikka} and Pauliina Kuutti and Juuso Paajanen and Seppo Parkkila and Paukkeri, {Erja Leena} and Markus Perola and Negar Pourjamal and Andreas Renner and Tuomas Rosberg and Taija Rutanen and Joni Savolainen and Haukka, {Jari K.} and Guyatt, {Gordon H.} and Tikkinen, {Kari A.O.}",

note = "Funding Information: The authors would like to thank the participating patients, their families, and the hospital staff. The Academy of Finland (335527; K.A.O.T.), Foundation of the Finnish Anti-Tuberculosis Association (K.A.O.T.), Helsinki University Hospital (TYH2022330; K.A.O.T.), P{\"a}ivikki and Sakari Sohlberg Foundation (K.A.O.T.), Sigrid Jus{\'e}lius Foundation (K.A.O.T.), Tampere Tuberculosis Foundation (J.R. and K.A.O.T.), and Tampere University Hospital State Research Funding (9AC085; J.R.) funded this study. World Health Organization (WHO) provided the study drug (remdesivir), donated by Gilead Sciences. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. Funding Information: The authors would like to thank the participating patients, their families, and the hospital staff. The Academy of Finland (335527; K.A.O.T.), Foundation of the Finnish Anti-Tuberculosis Association (K.A.O.T.), Helsinki University Hospital (TYH2022330; K.A.O.T.), P{\"a}ivikki and Sakari Sohlberg Foundation (K.A.O.T.), Sigrid Jus{\'e}lius Foundation (K.A.O.T.), Tampere Tuberculosis Foundation (J.R. and K.A.O.T.), and Tampere University Hospital State Research Funding (9AC085; J.R.) funded this study. World Health Organization (WHO) provided the study drug (remdesivir), donated by Gilead Sciences. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = oct,

doi = "10.1038/s41467-022-33825-5",

language = "English",

volume = "13",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

}

Solidarity Finland Investigators, Nevalainen, OPO, Horstia, S, Laakkonen, S, Rutanen, J, Mustonen, JMJ, Kalliala, IEJ, Ansakorpi, H, Kreivi, HR, Kuutti, P, Paajanen, J, Parkkila, S , Paukkeri, EL, Perola, M, Pourjamal, N, Renner, A, Rosberg, T, Rutanen, T, Savolainen, J, Haukka, JK, Guyatt, GH & Tikkinen, KAO 2022, 'Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial', Nature Communications, vol. 13, 6152. https://doi.org/10.1038/s41467-022-33825-5

TY - JOUR

T1 - Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial

AU - Solidarity Finland Investigators

AU - Nevalainen, Olli P.O.

AU - Horstia, Saana

AU - Laakkonen, Sanna

AU - Rutanen, Jarno

AU - Mustonen, Jussi M.J.

AU - Kalliala, Ilkka E.J.

AU - Ansakorpi, Hanna

AU - Kreivi, Hanna Riikka

AU - Kuutti, Pauliina

AU - Paajanen, Juuso

AU - Parkkila, Seppo

AU - Paukkeri, Erja Leena

AU - Perola, Markus

AU - Pourjamal, Negar

AU - Renner, Andreas

AU - Rosberg, Tuomas

AU - Rutanen, Taija

AU - Savolainen, Joni

AU - Haukka, Jari K.

AU - Guyatt, Gordon H.

AU - Tikkinen, Kari A.O.

N1 - Funding Information: The authors would like to thank the participating patients, their families, and the hospital staff. The Academy of Finland (335527; K.A.O.T.), Foundation of the Finnish Anti-Tuberculosis Association (K.A.O.T.), Helsinki University Hospital (TYH2022330; K.A.O.T.), Päivikki and Sakari Sohlberg Foundation (K.A.O.T.), Sigrid Jusélius Foundation (K.A.O.T.), Tampere Tuberculosis Foundation (J.R. and K.A.O.T.), and Tampere University Hospital State Research Funding (9AC085; J.R.) funded this study. World Health Organization (WHO) provided the study drug (remdesivir), donated by Gilead Sciences. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. Funding Information: The authors would like to thank the participating patients, their families, and the hospital staff. The Academy of Finland (335527; K.A.O.T.), Foundation of the Finnish Anti-Tuberculosis Association (K.A.O.T.), Helsinki University Hospital (TYH2022330; K.A.O.T.), Päivikki and Sakari Sohlberg Foundation (K.A.O.T.), Sigrid Jusélius Foundation (K.A.O.T.), Tampere Tuberculosis Foundation (J.R. and K.A.O.T.), and Tampere University Hospital State Research Funding (9AC085; J.R.) funded this study. World Health Organization (WHO) provided the study drug (remdesivir), donated by Gilead Sciences. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication. Publisher Copyright: © 2022, The Author(s).

PY - 2022/10

Y1 - 2022/10

N2 - We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.

AB - We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.

U2 - 10.1038/s41467-022-33825-5

DO - 10.1038/s41467-022-33825-5

M3 - Article

C2 - 36257950

AN - SCOPUS:85140079584

SN - 2041-1723

VL - 13

JO - Nature Communications

JF - Nature Communications

M1 - 6152

ER -

Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial

Abstract

Funding

Publication forum classification

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this